Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Reviews
Search Article 
  
Advanced search 
 
REVIEW ARTICLE
Year : 2018  |  Volume : 12  |  Issue : 24  |  Page : 157-165

The role of cucurbitacins in combating cancers: A mechanistic review


1 Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia
2 Department of Chemistry and Biochemistry, South Dakota State University, Brookings, SD, USA
3 Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia

Correspondence Address:
Dr. Narasimman Gurusamy
Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61441
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/phrev.phrev_17_18

Rights and Permissions

Cucurbitacins are highly oxidized tetracyclic triterpenoids from the Cucurbitaceae families. Several cucurbitacins, such as B, D, E, I, R, IIa, and dihydrocucurbitacin B, have been shown to possess antiproliferative and anticancer activities. Mechanistically, cucurbitacins induce cell cycle arrest at the G2/M phase and induce apoptosis through several mechanisms, such as the production of reactive oxygen species. In addition, they can inhibit the migration and invasion of cancer cells. Consistently, cucurbitacins have been shown to inhibit the Janus kinase-mediated activation of the transcription factor, signal transducer and activator of transcription. In addition, other receptor-mediated signaling pathways, such as ErbB, human epidermal growth factor receptor 2, and integrins, have also been inhibited by the cucurbitacin on cancer cells. Cucurbitacin treatments for various types of cancer have been shown to disrupt the cytoskeletal components such as actin, inhibit the expression of the proto-oncogenic proteins such as c-myc, and induce the expression of tumor suppressor proteins such as p53. Importantly, the synergistic anticancer activities of cucurbitacins have been observed when combined with established chemotherapeutic drugs, such as imatinib mesylate, paclitaxel, docetaxel, and gemcitabine. Cucurbitacins are a promising anticancer agent and can potentiate the effect of current chemotherapy drugs as well as reduce the serious side effects of these drugs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed334    
    Printed40    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal